Xiaoyun Luo, Chentao Jin, Hetian Chen, Jiaqi Niu, Congcong Yu, Xiaofeng Dou, Jing Wang, Junjie Wen, Hong Zhang, Mei Tian, Yan Zhong
{"title":"突触小泡糖蛋白 2 亚型 A 的 PET 成像用于缺血性中风的神经功能恢复。","authors":"Xiaoyun Luo, Chentao Jin, Hetian Chen, Jiaqi Niu, Congcong Yu, Xiaofeng Dou, Jing Wang, Junjie Wen, Hong Zhang, Mei Tian, Yan Zhong","doi":"10.1007/s00259-024-06904-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>[<sup>18</sup>F]SynVesT-1 is a novel radiopharmaceutical for assessing synaptic density in vivo. This study aims to investigate the potential of [<sup>18</sup>F]SynVesT-1 positron emission tomography (PET) in evaluating neurological recovery in the rat model of ischemic stroke, and to compare its performance with [<sup>18</sup>F]FDG PET.</p><p><strong>Methods: </strong>Sprague-Dawley rats were subjected to photothrombotic cerebral infarction, and safinamide was administered intraperitoneally from day 3 to day 14 post-stroke to alleviate neurological deficits. Cylinder test and forelimb placing test were performed to assess the neurological function. MRI, [<sup>18</sup>F]SynVesT-1 PET/CT and [<sup>18</sup>F]FDG PET/CT imaging were used to evaluate infarct volume, synaptic density, and cerebral glucose metabolism pre- and post-treatment. [<sup>18</sup>F]SynVesT-1 and [<sup>18</sup>F]FDG PET images were compared using Statistical Parametric Mapping (SPM) and region of interest (ROI)-based analysis. Post-mortem histological analysis was performed to validate PET images.</p><p><strong>Results: </strong>Safinamide treatment improved behavioral outcomes in stroke-damaged rats. Both [<sup>18</sup>F]SynVesT-1 and [<sup>18</sup>F]FDG PET detected stroke-induced injury, with the injured region being significantly larger in [<sup>18</sup>F]FDG PET than in [<sup>18</sup>F]SynVesT-1 PET. Compared with the saline group, radiotracer uptake in the injured area significantly increased in [<sup>18</sup>F]SynVesT-1 PET after safinamide treatment, whereas no notable change was observed in [<sup>18</sup>F]FDG PET. Additionally, [<sup>18</sup>F]SynVesT-1 PET imaging showed a better correlation with neurological function recovery than [<sup>18</sup>F]FDG PET. Post-mortem analysis revealed increased neuronal numbers, synaptic density, and synaptic neuroplasticity, as well as decreased glia activation in the stroke-injured area after treatment.</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]SynVesT-1 PET effectively quantified spatiotemporal dynamics of synaptic density in the rat model of stroke, and showed different capabilities in detecting stroke injury and neurological recovery compared with [<sup>18</sup>F]FDG PET. The utilization of [<sup>18</sup>F]SynVesT-1 PET holds promise as a potential non-invasive biomarker for evaluating ischemic stroke in conjunction with [<sup>18</sup>F]FDG PET.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"158-170"},"PeriodicalIF":8.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PET imaging of synaptic vesicle glycoprotein 2 subtype A for neurological recovery in ischemic stroke.\",\"authors\":\"Xiaoyun Luo, Chentao Jin, Hetian Chen, Jiaqi Niu, Congcong Yu, Xiaofeng Dou, Jing Wang, Junjie Wen, Hong Zhang, Mei Tian, Yan Zhong\",\"doi\":\"10.1007/s00259-024-06904-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>[<sup>18</sup>F]SynVesT-1 is a novel radiopharmaceutical for assessing synaptic density in vivo. This study aims to investigate the potential of [<sup>18</sup>F]SynVesT-1 positron emission tomography (PET) in evaluating neurological recovery in the rat model of ischemic stroke, and to compare its performance with [<sup>18</sup>F]FDG PET.</p><p><strong>Methods: </strong>Sprague-Dawley rats were subjected to photothrombotic cerebral infarction, and safinamide was administered intraperitoneally from day 3 to day 14 post-stroke to alleviate neurological deficits. Cylinder test and forelimb placing test were performed to assess the neurological function. MRI, [<sup>18</sup>F]SynVesT-1 PET/CT and [<sup>18</sup>F]FDG PET/CT imaging were used to evaluate infarct volume, synaptic density, and cerebral glucose metabolism pre- and post-treatment. [<sup>18</sup>F]SynVesT-1 and [<sup>18</sup>F]FDG PET images were compared using Statistical Parametric Mapping (SPM) and region of interest (ROI)-based analysis. Post-mortem histological analysis was performed to validate PET images.</p><p><strong>Results: </strong>Safinamide treatment improved behavioral outcomes in stroke-damaged rats. Both [<sup>18</sup>F]SynVesT-1 and [<sup>18</sup>F]FDG PET detected stroke-induced injury, with the injured region being significantly larger in [<sup>18</sup>F]FDG PET than in [<sup>18</sup>F]SynVesT-1 PET. Compared with the saline group, radiotracer uptake in the injured area significantly increased in [<sup>18</sup>F]SynVesT-1 PET after safinamide treatment, whereas no notable change was observed in [<sup>18</sup>F]FDG PET. Additionally, [<sup>18</sup>F]SynVesT-1 PET imaging showed a better correlation with neurological function recovery than [<sup>18</sup>F]FDG PET. Post-mortem analysis revealed increased neuronal numbers, synaptic density, and synaptic neuroplasticity, as well as decreased glia activation in the stroke-injured area after treatment.</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]SynVesT-1 PET effectively quantified spatiotemporal dynamics of synaptic density in the rat model of stroke, and showed different capabilities in detecting stroke injury and neurological recovery compared with [<sup>18</sup>F]FDG PET. The utilization of [<sup>18</sup>F]SynVesT-1 PET holds promise as a potential non-invasive biomarker for evaluating ischemic stroke in conjunction with [<sup>18</sup>F]FDG PET.</p>\",\"PeriodicalId\":11909,\"journal\":{\"name\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"volume\":\" \",\"pages\":\"158-170\"},\"PeriodicalIF\":8.6000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00259-024-06904-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-024-06904-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的：[18F]SynVesT-1 是一种用于评估体内突触密度的新型放射性药物。本研究旨在探讨[18F]SynVesT-1 正电子发射断层扫描（PET）在缺血性脑卒中大鼠模型中评估神经功能恢复的潜力，并比较其与[18F]FDG PET 的性能：方法：对 Sprague-Dawley 大鼠进行光栓性脑梗塞治疗，并在脑卒中后第 3 天至第 14 天腹腔注射沙芬胺以缓解神经功能缺损。进行圆筒测试和前肢放置测试以评估神经功能。核磁共振成像、[18F]SynVesT-1 PET/CT和[18F]FDG PET/CT成像用于评估治疗前后的梗死体积、突触密度和脑糖代谢。使用统计参数映射（SPM）和基于兴趣区域（ROI）的分析方法对[18F]SynVesT-1和[18F]FDG PET图像进行比较。为验证 PET 图像，还进行了死后组织学分析：结果：萨非那胺治疗改善了中风受损大鼠的行为结果。[18F]SynVesT-1和[18F]FDG PET都能检测到中风引起的损伤，[18F]FDG PET的损伤区域明显大于[18F]SynVesT-1 PET。与生理盐水组相比，经沙芬酰胺治疗后，[18F]SynVesT-1 PET 损伤区域的放射性示踪剂摄取量明显增加，而[18F]FDG PET 则无明显变化。此外，与[18F]FDG PET相比，[18F]SynVesT-1 PET成像与神经功能恢复的相关性更好。死后分析显示，治疗后中风损伤区域的神经元数量、突触密度和突触神经可塑性增加，胶质细胞激活减少：结论：[18F]SynVesT-1 PET 能有效量化脑卒中大鼠模型中突触密度的时空动态变化，与[18F]FDG PET 相比，[18F]SynVesT-1 PET 在检测脑卒中损伤和神经功能恢复方面表现出不同的能力。利用[18F]SynVesT-1 PET有望与[18F]FDG PET一起作为评估缺血性中风的潜在非侵入性生物标记物。
PET imaging of synaptic vesicle glycoprotein 2 subtype A for neurological recovery in ischemic stroke.
Purpose: [18F]SynVesT-1 is a novel radiopharmaceutical for assessing synaptic density in vivo. This study aims to investigate the potential of [18F]SynVesT-1 positron emission tomography (PET) in evaluating neurological recovery in the rat model of ischemic stroke, and to compare its performance with [18F]FDG PET.
Methods: Sprague-Dawley rats were subjected to photothrombotic cerebral infarction, and safinamide was administered intraperitoneally from day 3 to day 14 post-stroke to alleviate neurological deficits. Cylinder test and forelimb placing test were performed to assess the neurological function. MRI, [18F]SynVesT-1 PET/CT and [18F]FDG PET/CT imaging were used to evaluate infarct volume, synaptic density, and cerebral glucose metabolism pre- and post-treatment. [18F]SynVesT-1 and [18F]FDG PET images were compared using Statistical Parametric Mapping (SPM) and region of interest (ROI)-based analysis. Post-mortem histological analysis was performed to validate PET images.
Results: Safinamide treatment improved behavioral outcomes in stroke-damaged rats. Both [18F]SynVesT-1 and [18F]FDG PET detected stroke-induced injury, with the injured region being significantly larger in [18F]FDG PET than in [18F]SynVesT-1 PET. Compared with the saline group, radiotracer uptake in the injured area significantly increased in [18F]SynVesT-1 PET after safinamide treatment, whereas no notable change was observed in [18F]FDG PET. Additionally, [18F]SynVesT-1 PET imaging showed a better correlation with neurological function recovery than [18F]FDG PET. Post-mortem analysis revealed increased neuronal numbers, synaptic density, and synaptic neuroplasticity, as well as decreased glia activation in the stroke-injured area after treatment.
Conclusion: [18F]SynVesT-1 PET effectively quantified spatiotemporal dynamics of synaptic density in the rat model of stroke, and showed different capabilities in detecting stroke injury and neurological recovery compared with [18F]FDG PET. The utilization of [18F]SynVesT-1 PET holds promise as a potential non-invasive biomarker for evaluating ischemic stroke in conjunction with [18F]FDG PET.
期刊介绍：
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
